{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:01:13Z","timestamp":1776427273282,"version":"3.51.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T00:00:00Z","timestamp":1512518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The development of tyrosine-kinase inhibitors (TKIs) has improved survival of patients with chronic myeloid leukemia (CML). Some patients may become resistant to TKIs and require hematopoietic stem cell transplant (HSCT) that is highly gonadotoxic. Fertility preservation with ovarian stimulation might be indicated but is challenging if patients need to remain on TKIs until HSCT because TKIs may compromise follicular development and response to ovarian stimulation. We report the case of a patient with CML resistant to TKI and planned for an HSCT, in which treatment by TKI was replaced by interferon-\u03b1 before and during ovarian stimulation for fertility preservation. Successful ovarian stimulation was performed, allowing cryopreservation of nine zygotes. Hematopoietic stem cell transplantation was performed, and at present, 3 years later, the patient presents a sustained major molecular response.<\/jats:p>","DOI":"10.1634\/theoncologist.2017-0381","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T16:15:29Z","timestamp":1512576929000},"page":"719-721","source":"Crossref","is-referenced-by-count":15,"title":["Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-\u03b1"],"prefix":"10.1093","volume":"23","author":[{"given":"Smaranda","family":"Gazdaru","sequence":"first","affiliation":[{"name":"Reproductive Medicine Unit, Department Woman Mother Child, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucien","family":"Perey","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ensemble Hospitalier de la C\u00f4te, Morges, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Rosselet","sequence":"additional","affiliation":[{"name":"Hematology Unit, Etablissements Hospitaliers du Nord Vaudois, Yverdon-les-Bains, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Mathevet","sequence":"additional","affiliation":[{"name":"Service of Gynaecology, Department Woman Mother Child, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology Division, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Vulliemoz","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Unit, Department Woman Mother Child, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"2021122510551001500_onco12345-bib-0001","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Goldman","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122510551001500_onco12345-bib-0002","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"2021122510551001500_onco12345-bib-0003","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122510551001500_onco12345-bib-0004","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1634\/theoncologist.2011-0137","article-title":"Will imatinib compromise reproductive capacity?","volume":"16","author":"Zamah","year":"2011","journal-title":"The Oncologist"},{"key":"2021122510551001500_onco12345-bib-0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood.V95.1.62","article-title":"Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group","volume":"95","author":"Hochhaus","year":"2000","journal-title":"Blood"},{"key":"2021122510551001500_onco12345-bib-0006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbmt.2005.09.010","article-title":"Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study","volume":"12","author":"Chalandon","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"(suppl 2","key":"2021122510551001500_onco12345-bib-0007","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol"},{"key":"2021122510551001500_onco12345-bib-0008","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/molehr\/gal010","article-title":"Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis","volume":"12","author":"Hutt","year":"2006","journal-title":"Mol Hum Reprod"},{"key":"2021122510551001500_onco12345-bib-0009","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/jcp.22588","article-title":"Growth factors controlling ovarian functions","volume":"226","author":"Sirotkin","year":"2011","journal-title":"J Cell Physiol"},{"key":"2021122510551001500_onco12345-bib-0010","doi-asserted-by":"crossref","first-page":"e0152872","DOI":"10.1371\/journal.pone.0152872","article-title":"The tyrosine kinase inhibitor sunitinib affects ovulation but not ovarian reserve in mouse: A preclinical study","volume":"11","author":"Bernard","year":"2016","journal-title":"PLoS One"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/6\/719\/41916653\/oncolo_23_6_719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/6\/719\/41916653\/oncolo_23_6_719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:55:55Z","timestamp":1640429755000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/6\/719\/6439736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,6]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,12,6]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0381","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,1]]},"published":{"date-parts":[[2017,12,6]]}}}